Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1993
LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1K S Hirsch, C D Jones, J E Audia, et al.
Toxicology and Applied Pharmacology|February 1, 1990
Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male ratB L Neubauer, R L Goode, K L Best, et al.
Thrombosis Research|April 1, 1988
Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the ratG F Smith, B L Neubauer, J L Sundboom, et al.
Klinische Monatsblatter Fur Augenheilkunde|May 13, 1998
[Teleconsultation network for ophthalmology--experiences and results]G Zahlmann, H D Walther, B Liesenfeld, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 1, 1996
Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cellsM Kaefer, J E Audia, N Bruchovsky, et al.
The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.
Gynecologic Oncology|October 31, 2009
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrenceNabila Rasool, Amanda Nickles Fader, Leigh Seamon, et al.
Pageof 9